FDA Approves Mektovi (binimetinib) and Braftovi (encorafenib) in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations

On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (Braftovi and Mektovi, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news